An interesting case in the Dutch pharmaceutical landscape

Author
Published on
Category
Updates

In 2023, Isala Hospital (Zwolle, NL) became the first Dutch hospital to submit a registration for an in-house compounded medicinal product: prefilled ephedrine syringes. This was a pioneering step aimed at safeguarding both hospital compounding and the availability of essential medicines.

Obtaining and maintaining a marketing authorisation requires expertise far beyond pharmaceutical compounding, including regulatory affairs and lifecycle management.

While Isala’s application has not yet resulted in a registration, recently another entity -a collaboration between a hospital pharmacy and a pharmaceutical company- has now apparently become the first to obtain a registration for hospital-compounded ephedrine products, filled in prefilled syringes and ampoules.

This development demonstrates that hospital-compounded products can successfully make the transition to licensed medicines, whether driven by a hospital pharmacy alone or through a dedicated legal entity.

If you are a hospital(pharmacy) wanting to explore the possibilities of registering hospital compounded products, please feel free to contact us at info@starodub.nl

Explore Starodub updates

Great day at MEDICA in Düsseldorf!

When did you last stress-test your EU MDR regulatory strategy?

More data will not necessarily rescue a weak pharmaceutical dossier.

Jolanda Lamers-Lemmers
Management team member - Senior RA Consultant
Jolanda Lamers-Lemmers

Let's Connect

Talk to an expert